Testimonials
Sharon Williamson, OVA
Sue Allen, LUNG
Shannon Watson-Iezzi, BRE
Elizabeth Panke, OVA
Kathy Leach, BRE
Terry Gallant, NHL
Barby Crear, NHL
David Hanbidge, SCLC
George Kalogridis, NHL
Ingrid Ottesen, BRE
Byron Holstine, UPS
Subscribe to Our Newsletter
Testimonials
Kathy Leach
(Stage IV Breast Cancer)
In January of 2003, Kathy felt a lump in
her right breast. After seeking medical advice, a biopsy was
performed and her worst fears were confirmed. Kathy, a 45-year-old
mother of three, had aggressive breast cancer. When she went
for surgery, however, things went from bad to worse. Kathy
had metastatic disease with documented involvement of the
liver.
Despite advances in breast cancer management,
metastatic disease is still considered incurable. For that
reason, the doctors who were managing Kathy faced a serious
dilemma. Should they use strong combinations of chemotherapy
to hope against the odds that they could eliminate the disease
in the liver, or recognizing the low likelihood of cure, manage
Kathy with mild treatments, hoping to preserve the quality
of the time she had left?
Having known of the work of Dr. Robert Nagourney,
Director of Rational Therapeutics™ in Long Beach, CA, Kathy
asked her physicians in Cincinnati to send a portion of her
cancer to the California based laboratory. She then traveled
to California for an opinion with Dr. Nagourney. After a lengthy
review of the options, Dr. Nagourney explained that her highly
favorable drug sensitivity profile measured in the test tube
offered a rationale for strong drug combinations. Dr. Nagourney
reiterated to Kathy at the time of their meeting that many
physicians would prefer “milder” therapies. When
asked whether she wanted to try for the best possible outcome
with stronger combinations, Kathy said, in no uncertain terms,
that she wanted to “Go for it!”
Working in close collaboration with Kathy’s
Cincinnati based oncologist, with whom Dr. Nagourney had previously
shared patients, a series of treatments incorporating the
best possible drugs and combinations for Kathy was administered.
The response was dramatic, with complete resolution of all
detectable disease. Today, two years later, Kathy remains
in complete remission on a mild maintenance therapy with the
monoclonal antibody, Herceptin.
